share_log

華潤醫藥：公告華潤雙鶴截至2024年12月31日止年度的主要財務資料

CHINARES PHARMA: ANNOUNCEMENTPRINCIPAL FINANCIAL INFORMATION OFCR DOUBLE-CRANEFOR THE YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 19 10:56

Summary by Moomoo AI

華潤雙鶴於2025年3月19日發佈2024年度業績報告。2024年度，公司實現營業收入112.12億元人民幣，同比下降0.87%；歸屬上市公司股東淨利潤16.28億元人民幣，同比下降2.55%。扣除非經常性損益後的淨利潤14.32億元人民幣，同比增長16.14%。公司總資產達166.86億元人民幣，同比下降8.33%；上市公司股東應佔資產淨值104.08億元人民幣，同比下降14.78%。加權平均資產淨值回報率為15.07%，較上年增加1.8個百分點。經營活動所得現金流量淨額18.25億元人民幣，同比下降1.83%。公司董事會建議向全體股東派發2024年度現金股息，每10股派發3.71元人民幣（含稅），該分紅方案將提交股東週年大會審議。
華潤雙鶴於2025年3月19日發佈2024年度業績報告。2024年度，公司實現營業收入112.12億元人民幣，同比下降0.87%；歸屬上市公司股東淨利潤16.28億元人民幣，同比下降2.55%。扣除非經常性損益後的淨利潤14.32億元人民幣，同比增長16.14%。公司總資產達166.86億元人民幣，同比下降8.33%；上市公司股東應佔資產淨值104.08億元人民幣，同比下降14.78%。加權平均資產淨值回報率為15.07%，較上年增加1.8個百分點。經營活動所得現金流量淨額18.25億元人民幣，同比下降1.83%。公司董事會建議向全體股東派發2024年度現金股息，每10股派發3.71元人民幣（含稅），該分紅方案將提交股東週年大會審議。
China Resources Double-Crane Pharmaceutical published its performance report for the year 2024 on March 19, 2025. In 2024, the company achieved revenue of 11.212 billion yuan, a year-on-year decrease of 0.87%; net profit attributable to shareholders of the listed company was 1.628 billion yuan, a year-on-year decrease of 2.55%. After deducting non-recurring gains and losses, the net profit was 1.432 billion yuan, a year-on-year increase of 16.14%.The total assets of the company reached 16.686 billion yuan, a year-on-year decrease of 8.33%; the net asset value attributable to shareholders of the listed company was 10.408 billion yuan, a year-on-year decrease of 14.78%. The weighted average return on net assets was 15.07%, an increase of 1.8 percentage points compared to the previous year. The net cash flow from operating activities was 1.825 billion yuan, a year-on-year decrease of 1.83%.The Board of Directors proposed to distribute a cash dividend of 3.71 yuan (tax included) for every 10 shares to all shareholders for the year 2024, and this dividend proposal will be submitted for approval at the shareholders' annual meeting.
China Resources Double-Crane Pharmaceutical published its performance report for the year 2024 on March 19, 2025. In 2024, the company achieved revenue of 11.212 billion yuan, a year-on-year decrease of 0.87%; net profit attributable to shareholders of the listed company was 1.628 billion yuan, a year-on-year decrease of 2.55%. After deducting non-recurring gains and losses, the net profit was 1.432 billion yuan, a year-on-year increase of 16.14%.The total assets of the company reached 16.686 billion yuan, a year-on-year decrease of 8.33%; the net asset value attributable to shareholders of the listed company was 10.408 billion yuan, a year-on-year decrease of 14.78%. The weighted average return on net assets was 15.07%, an increase of 1.8 percentage points compared to the previous year. The net cash flow from operating activities was 1.825 billion yuan, a year-on-year decrease of 1.83%.The Board of Directors proposed to distribute a cash dividend of 3.71 yuan (tax included) for every 10 shares to all shareholders for the year 2024, and this dividend proposal will be submitted for approval at the shareholders' annual meeting.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 364

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
HIGHTIDE-B
02511
1.770
ANTENGENE-B
06996
4.180
EXTRAWELL PHAR
00858
0.046
AIM VACCINE
06660
4.320
UNITED LAB
03933
16.640
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1498 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK